Mitsubishi UFJ Asset Management Co. Ltd. Purchases 70,978 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 9.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 807,886 shares of the company's stock after buying an additional 70,978 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.07% of Teva Pharmaceutical Industries worth $17,159,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of TEVA. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares in the last quarter. Lingotto Investment Management LLP grew its position in shares of Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after buying an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 2.2% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after acquiring an additional 569,412 shares in the last quarter. State Street Corp lifted its position in Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock valued at $351,402,000 after acquiring an additional 1,778,268 shares during the period. Finally, AustralianSuper Pty Ltd boosted its stake in Teva Pharmaceutical Industries by 16.8% during the fourth quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock worth $203,268,000 after acquiring an additional 1,329,319 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have weighed in on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $1.45 during midday trading on Friday, reaching $13.40. 2,615,396 shares of the company's stock traded hands, compared to its average volume of 9,678,196. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a market cap of $15.19 billion, a price-to-earnings ratio of -9.32, a P/E/G ratio of 1.44 and a beta of 0.82. The stock has a 50 day moving average of $16.67 and a 200 day moving average of $18.04.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.